Tuesday, 2 June 201508:00 | Registration | | Session Chair: Catherine Prescott, Biolatris |
| | 09:00 | | Keynote Presentation Human ESC-derived Cardiomyocytes Michael Clements, Scientist, GE Healthcare, United Kingdom
|
| 10:00 | Stem Cells in Drug Discovery: Applications in Hit Discovery & Lead Optimisation Lorenz Mayr, Vice President, AstraZeneca Ltd, United Kingdom
The presentation will describe the use of cell lines derived from human induced pluripotent stem cells (iPSC) for target validation, hit discovery and safety assessment for various therapeutic areas within AstraZeneca. | 10:45 | Coffee and Networking in Exhibition Hall | 11:15 | Cardiac iPSCs for Drug Discovery Joseph Wu, Director/Professor, Stanford University School of Medicine, United States of America
Heart disease is the cause of morbidity and mortality in the industrialized world. While the use of human induced pluripotent stem cell (iPSCs) in regenerative medicine is a long-term goal. Recent technological advancement has enabled the generation of patient-specific and disease-specific human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) in vitro. iPSC-CMs carry all the genetic information and therefore may be an ideal platform for elucidating disease modeling, drug screening, and cell therapy. Here I will discuss recent advances in this technology in the cardiovascular field. | 12:00 | Disease Modelling and Drug Discovery in Neurological Disorders Zameel Cader, Director and Principal Scientist, IMI StemBANCC, University of Oxford, United Kingdom
My presentation will focus on stemBANCC and its progress in developing disease relevant models as well as how we hope to turn these into drug screening assays. | 12:45 | Lunch & Networking in Exhibition Hall | 13:30 | Poster Viewing Session
| | Session Chair: Joseph Wu, Stanford University School of Medicine |
| | 14:15 | Technology Spotlight: Implementation of iPS Cell Technology in Disease Research and Drug Discovery Dominic Hussey, Senior Account Manager, Cellular Dynamics International Inc
A major challenge in disease research and drug discovery is modelling human biology in physiologically relevant and predictive in vitro systems. Human induced pluripotent stem cell (iPSC) technology allows for the generation of virtually any cell type of the human body in unlimited quantities from a donor. | 14:30 | Developing Predictive Hepatocyte Models from Pluripotent Stem Cells David Hay, Chair of Tissue Engineering, MRC Centre for Regenerative Medicine, University of Edinburgh, United Kingdom
My presentation will focus on the delivery of hepatocytes from pluripotent stem cells. I will focus on the interdisciplinary collaborations we have employed to deliver optimised in vitro systems. While promising, there are key areas in the model which require attention. Data from a recent multi-centre project will be presented, providing a roadmap to improving the technology. | 15:15 | High Content Analysis using Stem Cells for Disease Modelling and Drug Discovery Davide Danovi, Director, Cell Phenotyping Platform, Kings College London, United Kingdom
The talk will present our cell phenotyping strategy, aimed at defining boundaries between health and selected diseases through high content image analysis of induced pluripotent stem cells at single cell level. | 16:00 | Coffee and Networking in Exhibition Hall | 16:30 | Technology Spotlight: Application of Axol Human iPS Cell-derived Cells for Drug Screening in a Dish Tristan Thwaites, Business Development & Product Specialist, Axol Bioscience
Human iPS-derived cells provide a great research tool to complement studies performed in vivo using animal models and are an easier to obtain/less heterogenous source of cells than primary and human ESCs. | 16:45 | iPS Cells for Muscle Disorders: From Regenerative Medicine to Disease Modelling Francesco Saverio Tedesco, Principal Research Associate, University College London, United Kingdom
I will discuss hurdles for the development of therapies for muscle disorders. I will present our platforms based upon iPS cells, inducible myogenesis and human artificial chromosomes. Extension of these technologies for tissue engineering and drug development will also be discussed. | 17:30 | High Content Biology & Cardiac Regeneration: Proliferation and Multi-lineage Differentiation Screens using Cardiac Progenitor Cells Lauren Drowley, Associate Principal Scientist, AstraZeneca, United Kingdom
Phenotypic screens for proliferation and multi-lineage differentiation with relevant human cardiac cell populations has resulted in identification of novel compounds and mechanisms. | 18:15 | End of Day One |
Wednesday, 3 June 2015 | Session Chair: David Hay, University of Edinburgh | Session Sponsors |
| | 09:00 | Developments from the EBiSC Timothy Allsopp, Co-ordinator IMI EBiSC Project, Pfizer, United Kingdom
| 09:45 | | 10:45 | Coffee and Networking in Exhibition Hall | 11:15 | Technology Spotlight: NeuroSafe: A Human Integrated in vitro Neurotoxicity Safety Platform using hiPSC- derived Neurons (Peri.4U neurons) Dietmar Hess, Lab Leader, Axiogenesis AG
| 11:30 | Disease Modeling and Phenotypic Drug Screening for Diabetic Cardiomyopathy Using Human Induced Pluripotent Stem Cells Faye Drawnel, Scientist, Pharma Research and Early Development, Roche, Switzerland
This presentation describes the development and characterization of an iPS-cell derived cardiomyocyte model of diabetic cardiomyopathy used in a phenotypic drug screen to identify candidate therapeutic molecules. | 12:15 | Lunch & Networking in Exhibition Hall | 13:30 | Poster Viewing Session
| | Session Chair: Stephen Minger, GE Healthcare |
| | 13:45 | Technology Spotlight: Leveraging Novel Technologies for Human iPSC-based Screening Xianmin Zeng, Associate Professor, Buck Institute for Research on Aging
Human induced pluripotent stem cell (iPSC) technology offers the benefits of a cell line coupled with the advantage of using human primary cells. However this requires standardization of iPSC generation and genetic modification, as well as the ability to obtain large numbers of differentiated cells in an assay ready format. | 14:00 | Using iPS Cells for Drug Screening and Diagnosis of Alzheimer’s Disease Chris Ward, Senior Lecturer, University of Manchester, United Kingdom
I will discuss the derivation of AD iPS cells and their use in high content screening and prognostic/diagnostic applications. | 14:45 | Coffee and Networking in Exhibition Hall | 15:15 | Stem Cell Derived Cardiomyocytes and Drug Safety: The Comprehensive In vitro Proarrhythmia Assay (CiPA) Initiative and Beyond Gary Gintant, Senior Research Fellow, Abbvie, United States of America
| 16:00 | Close of Conference |
|